Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HNF4A | P41235 | 2/20 | 0.48 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828428 | 0.84 | BACE1 (0.59) | ALOX5KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL51661 | 0.83 | ALOX5 (0.61) | ALOX5KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL29059236 | 0.82 | ALOX5 (0.59) | ALOX5KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL4199791 | 0.80 | ALOX5 (0.57) | ALOX5KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL30083378 | 0.80 | TAAR1 (0.48) | ALOX5KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL27292719 | 0.80 | ALOX5 (0.57) | ALOX5KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL2574818 | 0.80 | TAAR1 (0.48) | ALOX5KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL3301299 | 0.79 | GABRA1 (0.59) | ALOX5KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL28053825 | 0.79 | ALOX5 (0.83) | ALOX5KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL11724859 | 0.78 | AKR1B1 (0.59) | ALOX5KDM4ELMNAGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2950793-B1 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES | BioVersys AG (CH) | 2020-04-01 | — | — | EP | disclosed |
| US-9682079-B2 | Composition for treatment of pathogens that are resistant to tetracyclines | BioVersys AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9682079-B2 | Composition for treatment of pathogens that are resistant to tetracyclines | BioVersys AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9682079-B2 | Composition for treatment of pathogens that are resistant to tetracyclines | BioVersys AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20150359791-A1 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES | BioVersys AG (CH) | 2015-12-17 | — | — | US | disclosed |
| US-20150359791-A1 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES | BioVersys AG (CH) | 2015-12-17 | — | — | US | disclosed |
| US-20150359791-A1 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES | BioVersys AG (CH) | 2015-12-17 | — | — | US | disclosed |
| EP-2950793-A1 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES | Bioversys AG (CH) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014118361-A1 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES | BioVersys AG (CH) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014118361-A1 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES | BioVersys AG (CH) | 2014-08-07 | — | — | WO | disclosed |
| EP-2762134-A1 | Composition for treatment of pathogens that are resistant to tetracyclines | Bioversys AG (CH) | 2014-08-06 | — | — | EP | disclosed |
| EP-2762134-A1 | Composition for treatment of pathogens that are resistant to tetracyclines | Bioversys AG (CH) | 2014-08-06 | — | — | EP | disclosed |
| EP-1698635-B1 | BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-7547680-B2 | Benzimidazole derivatives and medical uses thereof | KISSEI PHARMACEUTICALS, CO., LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20080038242-A1 | Benzimidazole derivatives and medical uses thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1698635-A1 | BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038242-A1 | Benzimidazole derivatives and medical uses thereof | SLCO1B3, SLCO2A1, SLCO2B1 | ALOX5 1789/4885KDM4E 2804/4885MEN1 3420/4885 |
| US-20150359791-A1 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES | TET1, TET3, TCEA1 | ALOX5 4552/4885KDM4E 1941/4885MEN1 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.